Transient protection of normal cells during chemotherapy
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, improved protection of healthy cells is disclosed using disclosed compounds that act as highly selective and short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders.
1. A compound of Formula:
or a pharmaceutically acceptable salt thereof;
wherein:
R 10 is —C(O)-R 12 , or C(O)O—R 13 ;
R 12 is NHR A or R A ;
R 13 is R A ;
R A is C 1 -C 8 alkyl, cycloalkylalkyl, TT-RR, C 1 -C 8 cycloalkyl containing one or more heteroatoms selected from N, O, and S, or C 1 -C 8 cycloalkyl;
TT is C 1 -C 8 alkylene or C 3 -C 8 cycloalkylene linker; and
RR is hydroxyl, C 1 -C 6 alkoxy, amino, C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 6 -C 10 aryl, heteroaryl having one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O, and S, C 3 -C 10 carbocycle, or heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O, and S.
2. The compound of claim 1 , wherein R 10 is —C(O)—R 12 .
3. The compound of claim 2 , wherein R 12 is R A .
4. The compound of claim 3 , wherein R A is C 1 -C 8 alkyl.
5. The compound of claim 2 , wherein R 12 is NHR A .
6. The compound of claim 5 , wherein R A is C 1 -C 8 alkyl.
7. The compound of claim 1 , wherein R 10 is —C(O)O—R 13 .
8. The compound of claim 1 , of Formula:
9. The compound of claim 1 , of Formula:
10. The compound of claim 9 , wherein R 10 is —C(O)—R 12 .
11. The compound of claim 10 , wherein R 12 is R A .
12. The compound of claim 11 , wherein R A is C 1 -C 8 alkyl.
13. The compound of claim 10 , wherein R 12 is NHR A .
14. The compound of claim 13 , wherein R A is C 1 -C 8 alkyl.
15. A pharmaceutical composition comprising an effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.
16. A compound of Formula:
or a pharmaceutically acceptable salt thereof;
wherein:
each R 1 is independently aryl, alkyl, cycloalkyl, or haloalkyl;
or two R 1 's on adjacent ring atoms together with the ring atoms to which they are attached form a 3-8-membered cycle
R 10 is —C(O)—R 12 , or —C(O)O—R 13 ;
R 12 is NHR A or R A ;
R 13 is R A ;
R A is C 1 -C 8 alkyl, cycloalkylalkyl, -TT-RR, C 1 -C 8 cycloalkyl containing one or more heteroatoms selected from N, O, and S, or C 1 -C 8 cycloalkyl;
TT is C 1 -C 8 s alkylene or C 3 -C 8 cycloalkylene linker; and
RR is hydroxyl, C 1 -C 6 alkoxy, amino, C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 6 -C 10 aryl, heteroaryl having one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O, and S, C 3 -C 10 carbocycle, or heterocycle comprising one or two 5- or 6-member rings and 1-4 heteroatoms selected from N, O and S.
17. The compound of claim 16 , wherein R 10 is —C(O)—R 12 .
18. The compound of claim 17 , wherein R 12 is R A .
19. The compound of claim 18 , wherein R A is C 1 -C 8 alkyl.
20. The compound of claim 17 , wherein R 12 is NHR A .
21. The compound of claim 20 , wherein R A is C 1 -C 8 alkyl.